Indian Pharmaceutical Alliance

Home
India
Santacruz
Indian Pharmaceutical Alliance

IPA is an alliance of 23 leading Indian pharmaceutical companies, committed to patient care in India and across the world.

30/12/2025

26/12/2025

As the year comes to a close, Sudarshan Jain outlines the roadmap for the Indian pharmaceutical industry. The journey toward 2047 is shaped by decisions and actions taken today across research, manufacturing, and innovation.

19/12/2025

Report: The Importance of Single Global Development of Generic and Biosimilar Medicines for Patient Access

Discover how harmonized regulatory standards can dismantle global barriers, reduce development costs, and accelerate the delivery of affordable medicines to patients worldwide. Backed by rigorous academic research, this report makes the definitive case for a streamlined, single global development pathway to improve healthcare equity.

Read the full report here: www.ipa-india.org

18/12/2025

Strengthening regulatory enforcement through capacity building.

The Indian Pharmaceutical Alliance (IPA) was represented by Dr. Keshav Kumar, Senior Technical Advisor, at a two-day national training programme organised by the National Institute of Health and Family Welfare - NIHFW, India (NIHFW) on 12–13 December 2025 in New Delhi.

The programme focused on enforcement powers under the Drugs & Cosmetics Act, 1940, in the context of the transition from CrPC to the Bharatiya Nagarik Suraksha Sanhita (BNSS), 2023.

By bringing together legal, judicial, and enforcement perspectives, the initiative reinforced the importance of lawful procedures, evidence integrity, inter-agency coordination, and constitutional safeguards to ensure effective and credible regulatory action.

IPA’s participation reflects its continued commitment to quality, patient safety, and strengthening India’s pharmaceutical regulatory framework through collaboration.

04/12/2025

By 2030, drug patents worth over $250 billion will expire globally – a huge opportunity for India to lead in generics, biosimilars, and affordable innovation. A balanced intellectual property framework will be key to supporting scale, quality, and equitable access.

01/12/2025

On , we recognize that the fight against HIV relies on continuous, affordable access to treatment. Two decades ago, Indian Pharma sparked a revolution, bringing lifesaving triple therapy to millions for under $1 a day. Today, over 70% of the world's Antiretroviral Therapy comes from India.

> We remain committed to:
> Global ARV affordability.
> Advancing new therapies.
> Supporting the UNAIDS 2030 goals.

Sustained access isn't just support, it's the only way to for good.

Swipe through to learn more about our commitment.

27/11/2025

Union Minister of Commerce & Industry, Piyush Goyal, met with leaders from the Indian Pharma industry and the Indian Pharmaceutical Alliance. Discussions focused on innovation, investment, and scaling manufacturing capabilities.

Read more: ‪https://www.tribuneindia.com/news/business/piyush-goyal-meets-pharma-stakeholders-to-discuss-growth-regulation-amid-global-tariff-concerns/‬

Department of Commerce, GoI

Union Minister of Commerce and Industry, Piyush Goyal, held an interaction with key stakeholders from Indias pharmaceutical ecosystem, focusing on strengthening industry growth and regulatory reforms.

24/11/2025

Navigating the Next Decade of Indian Pharma.

What are the strategic imperatives driving the industry forward?
The latest from The Economic Times brings together two powerhouses: Nandini Piramal (Chairperson, Piramal Pharma) and Arjun Juneja (Chief Operating Officer, Mankind Pharma Limited).

In a wide-ranging dialogue with Vikas Dandekar, they cut across the critical issues of quality, disruptive technology, and the business realities shaping Indian Pharma today. Get a clearer view of how leaders are positioning their organizations for the decade ahead.

Watch the full interview here: https://tinyurl.com/tzr7vhfs

Video Credit: The Economic Times

20/11/2025

20/11/2025

Congratulations to Dilip Shanghvi, Executive Chairman of Sun Pharmaceutical Industries Limited, on being recognized as one of the Best CEOs in the Large Category at the Fortune India Best CEOs Awards 2025.

It is a moment of pride for us as our Executive Chairman, Dilip Shanghvi, is honoured as one of the Best CEOs (Large Category) at Fortune India’s India’s Best CEOs Awards 2025.

This recognition celebrates not just business excellence, but the quiet strength, humility, and compassion that define his leadership. His belief in empowering people and building trust continues to shape who we are, and how we work every day.

19/11/2025

18/11/2025

Address

Santacruz

Website

https://www.ipa-india.org/

Alerts

Be the first to know and let us send you an email when Indian Pharmaceutical Alliance posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Indian Pharmaceutical Alliance:

Shortcuts

Want your practice to be the top-listed Clinic in Santacruz?

About IPA

The Indian Pharmaceutical Alliance (IPA) was established in the year 1999 in Mumbai. IPA represents research-based National Pharmaceutical Companies in India. The IPA works closely with the Government on policy-related matters and seeks to imbibe the experiences of the generic pharmaceutical industry internationally. It is also partnering with the Government in the evolution of a patent regime and up-gradation of the regulatory regime in India.

It consists of 24 member companies. IPA accounts for over 85 percent of the private sector investment in pharmaceutical research and development. We contribute more than 80 percent of the country's exports of drugs and pharmaceuticals and service over 57 percent of the domestic market.

30/12/2025

26/12/2025

19/12/2025

18/12/2025

04/12/2025

01/12/2025

27/11/2025

24/11/2025

20/11/2025

20/11/2025

19/11/2025

18/11/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category

About IPA